325 related articles for article (PubMed ID: 23652555)
1. FGF23-induced hypophosphatemia persists in Hyp mice deficient in the WNT coreceptor Lrp6.
Uchihashi K; Nakatani T; Goetz R; Mohammadi M; He X; Razzaque MS
Contrib Nephrol; 2013; 180():124-37. PubMed ID: 23652555
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model.
Nakatani T; Ohnishi M; Razzaque MS
FASEB J; 2009 Nov; 23(11):3702-11. PubMed ID: 19584304
[TBL] [Abstract][Full Text] [Related]
3. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.
Liu S; Tang W; Zhou J; Vierthaler L; Quarles LD
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1636-44. PubMed ID: 17848631
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic role of Fgf23 in Hyp mice.
Liu S; Zhou J; Tang W; Jiang X; Rowe DW; Quarles LD
Am J Physiol Endocrinol Metab; 2006 Jul; 291(1):E38-49. PubMed ID: 16449303
[TBL] [Abstract][Full Text] [Related]
5. A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells.
Ichikawa S; Austin AM; Gray AK; Econs MJ
J Bone Miner Res; 2012 Feb; 27(2):453-60. PubMed ID: 22006791
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of the DMP1 C-terminal fragment stimulates FGF23 and exacerbates the hypophosphatemic rickets phenotype in Hyp mice.
Martin A; David V; Li H; Dai B; Feng JQ; Quarles LD
Mol Endocrinol; 2012 Nov; 26(11):1883-95. PubMed ID: 22930691
[TBL] [Abstract][Full Text] [Related]
7. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling.
Martin A; Liu S; David V; Li H; Karydis A; Feng JQ; Quarles LD
FASEB J; 2011 Aug; 25(8):2551-62. PubMed ID: 21507898
[TBL] [Abstract][Full Text] [Related]
8. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia.
Yuan B; Takaiwa M; Clemens TL; Feng JQ; Kumar R; Rowe PS; Xie Y; Drezner MK
J Clin Invest; 2008 Feb; 118(2):722-34. PubMed ID: 18172553
[TBL] [Abstract][Full Text] [Related]
9. Altered renal FGF23-mediated activity involving MAPK and Wnt: effects of the Hyp mutation.
Farrow EG; Summers LJ; Schiavi SC; McCormick JA; Ellison DH; White KE
J Endocrinol; 2010 Oct; 207(1):67-75. PubMed ID: 20675303
[TBL] [Abstract][Full Text] [Related]
10. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.
Quarles LD
Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E1-9. PubMed ID: 12791601
[TBL] [Abstract][Full Text] [Related]
11. The wrickkened pathways of FGF23, MEPE and PHEX.
Rowe PS
Crit Rev Oral Biol Med; 2004 Sep; 15(5):264-81. PubMed ID: 15470265
[TBL] [Abstract][Full Text] [Related]
12. ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate.
David V; Martin A; Hedge AM; Drezner MK; Rowe PS
Am J Physiol Renal Physiol; 2011 Mar; 300(3):F783-91. PubMed ID: 21177780
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity.
Liu S; Rowe PS; Vierthaler L; Zhou J; Quarles LD
J Endocrinol; 2007 Jan; 192(1):261-7. PubMed ID: 17210763
[TBL] [Abstract][Full Text] [Related]
14. Sclerostin antibody improves phosphate metabolism hormones, bone formation rates, and bone mass in adult Hyp mice.
Carpenter KA; Davison R; Shakthivel S; Anderson KD; Ko FC; Ross RD
Bone; 2022 Jan; 154():116201. PubMed ID: 34537437
[TBL] [Abstract][Full Text] [Related]
15. SPR4-peptide alters bone metabolism of normal and HYP mice.
Zelenchuk LV; Hedge AM; Rowe PS
Bone; 2015 Mar; 72():23-33. PubMed ID: 25460577
[TBL] [Abstract][Full Text] [Related]
16. Eldecalcitol Causes FGF23 Resistance for Pi Reabsorption and Improves Rachitic Bone Phenotypes in the Male Hyp Mouse.
Kaneko I; Segawa H; Ikuta K; Hanazaki A; Fujii T; Tatsumi S; Kido S; Hasegawa T; Amizuka N; Saito H; Miyamoto KI
Endocrinology; 2018 Jul; 159(7):2741-2758. PubMed ID: 29878089
[TBL] [Abstract][Full Text] [Related]
17. Dentoalveolar Defects in the
Zhang H; Chavez MB; Kolli TN; Tan MH; Fong H; Chu EY; Li Y; Ren X; Watanabe K; Kim DG; Foster BL
J Dent Res; 2020 Apr; 99(4):419-428. PubMed ID: 31977267
[TBL] [Abstract][Full Text] [Related]
18. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.
Rowe PS
Crit Rev Eukaryot Gene Expr; 2012; 22(1):61-86. PubMed ID: 22339660
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of human PHEX under the human beta-actin promoter does not fully rescue the Hyp mouse phenotype.
Erben RG; Mayer D; Weber K; Jonsson K; Jüppner H; Lanske B
J Bone Miner Res; 2005 Jul; 20(7):1149-60. PubMed ID: 15940367
[TBL] [Abstract][Full Text] [Related]
20. Dosage effect of a Phex mutation in a murine model of X-linked hypophosphatemia.
Ichikawa S; Gray AK; Bikorimana E; Econs MJ
Calcif Tissue Int; 2013 Aug; 93(2):155-62. PubMed ID: 23700148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]